Abstract

The circadian clock component NR1D1 (REVERBα) is considered a dominant regulator of lipid metabolism, with global Nr1d1 deletion driving dysregulation of white adipose tissue (WAT) lipogenesis and obesity. However, a similar phenotype is not observed under adipocyte-selective deletion (Nr1d1Flox2-6:AdipoqCre), and transcriptional pro1ling demonstrates that, under basal conditions, direct targets of NR1D1 regulation are limited, and include the circadian clock and collagen dynamics. Under high-fat diet (HFD) feeding, Nr1d1Flox2-6:AdipoqCre mice do manifest profound obesity, yet without the accompanying WAT in2ammation and 1brosis exhibited by controls. Integration of the WAT NR1D1 cistrome with differential gene expression reveals broad control of metabolic processes by NR1D1 which is unmasked in the obese state. Adipocyte NR1D1 does not drive an anticipatory daily rhythm in WAT lipogenesis, but rather modulates WAT activity in response to alterations in metabolic state. Importantly, NR1D1 action in adipocytes is critical to the development of obesity-related WAT pathology and insulin resistance.

Data availability

RNA-seq data generated in the course of this study has been uploaded to ArrayExpress and is available at http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-8840. For reviewer access, the following login details can be used: username "Reviewer_E-MTAB-8840", password "IGGB44Tx". ChIP-seq data generated in the course of this study has been uploaded to ArrayExpress and is available at http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-10573. For reviewer access, the follow690ing login details can be used: username "Reviewer_E-MTAB-10573", password "nncbrjdh". Access to these datasets will be opened to the public upon acceptance of themanuscript. Raw proteomics data has been uploaded to Mendeley Data . Output of 'omics analyses (proteomics, edgeR, stageR, ReactomePA outputs, peak calling) are provided in the Source Data Files.

The following data sets were generated

Article and author information

Author details

  1. Ann Louise Hunter

    Centre for Biological Timing, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3874-4852
  2. Charlotte E Pelekanou

    Centre for Biological Timing, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.
  3. Nichola J Barron

    Centre for Biological Timing, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.
  4. Rebecca C Northeast

    Centre for Biological Timing, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3121-2802
  5. Magdalena Grudzien

    Centre for Biological Timing, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.
  6. Antony D Adamson

    Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.
  7. Polly Downton

    Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1617-6153
  8. Thomas Cornfield

    OCDEM, University of Oxford, Oxford Centre for Diabetes, Endocrinology and Metabolism, United Kingdom
    Competing interests
    No competing interests declared.
  9. Peter S Cunningham

    Centre for Biological Timing, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.
  10. Jean-Noel Billaud

    QIAGEN Bioinformatics, Redwood City, United States
    Competing interests
    Jean-Noel Billaud, J-N.B. is an employee of Qiagen..
  11. Leanne Hodson

    OCDEM, University of Oxford, Oxford Centre for Diabetes, Endocrinology and Metabolism, United Kingdom
    Competing interests
    No competing interests declared.
  12. Andrew Loudon

    Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.
  13. Richard D Unwin

    Stoller Biomarker Discovery Centre, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.
  14. Mudassar Iqbal

    Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.
  15. David Ray

    OCDEM, University of Oxford, Oxford Centre for Diabetes, Endocrinology and Metabolism, United Kingdom
    Competing interests
    No competing interests declared.
  16. David A Bechtold

    Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
    For correspondence
    david.bechtold@manchester.ac.uk
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8676-8704

Funding

Biotechnology and Biological Sciences Research Council (BB/I018654/1)

  • David A Bechtold

Medical Research Council (MR/N021479/1)

  • Ann Louise Hunter

Medical Research Council (MR/P00279X/1)

  • David A Bechtold

Medical Research Council (MR/P011853/1)

  • David Ray

Medical Research Council (MR/P023576/1)

  • David Ray

Wellcome Trust (107849/Z/15/Z)

  • David Ray

Wellcome Trust (107851/Z/15/Z)

  • David Ray

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All experiments described here were conducted in accordance with local requirements and licenced under the UK Animals (Scientific Procedures) Act 1986, project licence number 70/8558 (licence holder Dr. David A Bechtold). Procedures were approved by the University of Manchester Animal Welfare and Ethical Review Body (AWERB).

Copyright

© 2021, Hunter et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,401
    views
  • 564
    downloads
  • 42
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ann Louise Hunter
  2. Charlotte E Pelekanou
  3. Nichola J Barron
  4. Rebecca C Northeast
  5. Magdalena Grudzien
  6. Antony D Adamson
  7. Polly Downton
  8. Thomas Cornfield
  9. Peter S Cunningham
  10. Jean-Noel Billaud
  11. Leanne Hodson
  12. Andrew Loudon
  13. Richard D Unwin
  14. Mudassar Iqbal
  15. David Ray
  16. David A Bechtold
(2021)
Adipocyte NR1D1 dictates adipose tissue expansion during obesity
eLife 10:e63324.
https://doi.org/10.7554/eLife.63324

Share this article

https://doi.org/10.7554/eLife.63324

Further reading

    1. Cell Biology
    2. Immunology and Inflammation
    Alejandro Rosell, Agata Adelajda Krygowska ... Esther Castellano Sanchez
    Research Article

    Macrophages are crucial in the body’s inflammatory response, with tightly regulated functions for optimal immune system performance. Our study reveals that the RAS–p110α signalling pathway, known for its involvement in various biological processes and tumourigenesis, regulates two vital aspects of the inflammatory response in macrophages: the initial monocyte movement and later-stage lysosomal function. Disrupting this pathway, either in a mouse model or through drug intervention, hampers the inflammatory response, leading to delayed resolution and the development of more severe acute inflammatory reactions in live models. This discovery uncovers a previously unknown role of the p110α isoform in immune regulation within macrophages, offering insight into the complex mechanisms governing their function during inflammation and opening new avenues for modulating inflammatory responses.

    1. Cell Biology
    Affiong Ika Oqua, Kin Chao ... Alejandra Tomas
    Research Article

    G protein-coupled receptors (GPCRs) are integral membrane proteins which closely interact with their plasma membrane lipid microenvironment. Cholesterol is a lipid enriched at the plasma membrane with pivotal roles in the control of membrane fluidity and maintenance of membrane microarchitecture, directly impacting on GPCR stability, dynamics, and function. Cholesterol extraction from pancreatic beta cells has previously been shown to disrupt the internalisation, clustering, and cAMP responses of the glucagon-like peptide-1 receptor (GLP-1R), a class B1 GPCR with key roles in the control of blood glucose levels via the potentiation of insulin secretion in beta cells and weight reduction via the modulation of brain appetite control centres. Here, we unveil the detrimental effect of a high cholesterol diet on GLP-1R-dependent glucoregulation in vivo, and the improvement in GLP-1R function that a reduction in cholesterol synthesis using simvastatin exerts in pancreatic islets. We next identify and map sites of cholesterol high occupancy and residence time on active vs inactive GLP-1Rs using coarse-grained molecular dynamics (cgMD) simulations, followed by a screen of key residues selected from these sites and detailed analyses of the effects of mutating one of these, Val229, to alanine on GLP-1R-cholesterol interactions, plasma membrane behaviours, clustering, trafficking and signalling in INS-1 832/3 rat pancreatic beta cells and primary mouse islets, unveiling an improved insulin secretion profile for the V229A mutant receptor. This study (1) highlights the role of cholesterol in regulating GLP-1R responses in vivo; (2) provides a detailed map of GLP-1R - cholesterol binding sites in model membranes; (3) validates their functional relevance in beta cells; and (4) highlights their potential as locations for the rational design of novel allosteric modulators with the capacity to fine-tune GLP-1R responses.